Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills
- Posted on February 25, 2026
- By Forbes
- 1 Views
Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills
The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions of successors to Ozempic and Wegovy.
